Sort
15,842 grants matching “pancreatic cancer”
Penn Quantitative MRI Resource for Pancreatic Cancer
$588,964Rong Zhou · University Of Pennsylvania · U24 · FY2019 · CA
AB Sciex 6500+ QTRAP with Selexion for ultra-sensitive metabolomics and lipidomics
$588,578Irwin Jack Kurland · Albert Einstein College Of Medicine, Inc · S10 · FY2017 · OD
Alcohol Reduction in Medical Illnesses:HCV as Prototype
$588,569Neal V Dawson · Case Western Reserve University · R01 · FY2006 · AA
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
$588,460James A Stewart · University Of Wisconsin-Madison · U10 · FY2007 · CA
Targeting the Metabolic Basis of Cachexia in Pancreatic Cancer
$588,368Pankaj Kumar Singh · University Of Nebraska Medical Center · R01 · FY2019 · CA
TOWARDS PRECISION PREVENTION: TESTING A NOVEL RISK PREDICTION ALGORITHM IN PANCREATIC CANCER
$588,346The Institute For Cancer Research · · FY2017 · Department of the Army
A Dual Molecular/Tumor Targeting Therapy for PanCa
$588,264Synergene Therapeutics, Inc. · R42 · FY2005 · CA
Immune cell control of ovarian cancer
$587,759Christina Annunziata · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Collaborative Research: Next-Generation Model Checking and Abstract Interpretation with a Focus on Embedded Control and Systems Biology
$587,670Nancy Griffeth · Research Foundation Of The City University Of New York (Lehman) · · FY2009 · CSE
Early detection of pancreatic cancer in diabetics
$587,611Ru Chen · University Of Washington · R01 · FY2017 · CA
Understanding how metabolic heterogeneity in cancer affects the tumor microenvironment and anti-tumor immunity
$587,283Susan M Kaech · Salk Institute For Biological Studies · R01 · FY2023 · CA
Understanding how metabolic heterogeneity in cancer affects the tumor microenvironment and anti-tumor immunity
$587,283Susan M Kaech · Salk Institute For Biological Studies · R01 · FY2022 · CA
Characterizing the sources, mechanisms, and translational relevance of microbial TMAO in driving anti-tumor immunity in pancreatic cancer.
$587,277Rahul Suresh Shinde · Wistar Institute · R37 · FY2024 · CA
Therapeutic approaches for LKB1-deficient non-small cell lung cancer
$587,093John V. Heymach · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA
North American Pancreatitis Study 2 (NAPS2)
$587,023University Of Pittsburgh At Pittsburgh · R01 · FY2003 · DK
Advancing Precision Oncology in a Humanized, Fully Autologous Mouse Model
$587,012Ryan C Fields · Washington University · R01 · FY2023 · CA
Advancing Precision Oncology in a Humanized, Fully Autologous Mouse Model
$587,011Ryan C Fields · Washington University · R01 · FY2022 · CA
The "dark immunopeptidome" as a source of CD8 T cell epitopes in type 1 diabetes
$586,996Teresa P Dilorenzo · Albert Einstein College Of Medicine · R01 · FY2024 · DK
Role of Fibroblasts, Myeloid Cells and Matrix in PDAC
$586,932Raghu Kalluri · University Of Tx Md Anderson Can Ctr · U01 · FY2013 · CA
Ras-mediated signals in human epithelial cell transformation and metastasis
$586,874Kathleen Kelly · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Zonisamide for the Treatment of Alcohol Use Disorder in the Addiction Neuroclinical Assessment Framework
$586,597Sterling M McPherson · Washington State University · R01 · FY2024 · AA
New Therapuetics for Pancreatic Cancer
$586,363Martin Ernesto Fernandez-Zapico · Mayo Clinic Rochester · R01 · FY2023 · CA
The Opioid Cohort Consortium (OPICO) to investigate the effects of using opioids on cancer risk
$586,334Mahdi Sheikh · International Agency For Res On Cancer · U01 · FY2024 · CA
Fully Quantitative Low-Dose, Motion-Resolved Dynamic Contrast-Enhanced MRI in Pancreatic Adenocarcinoma
$586,150Anthony G Christodoulou · Cedars-Sinai Medical Center · R01 · FY2022 · EB
Fully Quantitative Low-Dose, Motion-Resolved Dynamic Contrast-Enhanced MRI in Pancreatic Adenocarcinoma
$586,150Anthony G Christodoulou · Cedars-Sinai Medical Center · R01 · FY2023 · EB